



Image: Takeda



With: **Udo J. Vetter**
Head of the Control Board
of Vetter Companies



Gert Moelgaard
VP Innovation & Business Dev.
NNE Pharmaplan



Jörg Zimmermann
Dir. Process Dev. & Implemen-
tation, Vetter Pharma-Fertigung



Dr Daniel Müller
GMP Inspector
Regierungsprärs. Tübingen



James Drinkwater
Process & Compliance Dir.
Bioquell

- ECA Conference
Sterile Fill & Finish
- ECA Conference
Current Aseptic Technologies
- ECA Conference
Glass - Glass Breakage - Delamination
- ECA Conference
Barrier Systems (Isolators/RABS)



Pharmaceutical Quality
Training. Conferences. Services.

Media Partner:



Greeting



Dear Colleagues,

on 19/20 March 2013 the 15th Pharma Congress will take place in Düsseldorf. It has already become a tradition that the industry comes together to this event.

During this Congress many international projects will be introduced that are characterised through current developments and innovations. The various conferences will also be accompanied again by the large trade show PharmaTechnica showcasing more than 80 exhibitors.

It is the goal of this international event to present lectures as technical applications "from users for users", thus primarily concentrating on the practical benefit. The current technical state of the art will be demonstrated through presentations in the areas sterile technology, packaging, manufacture of solid dosage forms, automation and energy management. At the same time delegates take advantage of the Congress for an information and experience exchange, and this exchange certainly also contributes for finding a solution for the one or other problem.

Due to the globalisation we are all dependent on building and maintaining "good and productive" networks to stay on top of current developments and trends and to find out more about interesting and sustainable solutions.

I look forward to welcoming you to the Pharma Congress 2013. It will most certainly be another interesting event to be part of.

Yours sincerely
 Franz Maier
Prof. Dipl. Ing. Franz Maier
 Nycomed GmbH

The Pharma Congress Overview

Pharma Congress Overview			
Conference	<u>One day ticket 690 EUR</u>	19 March	20 March
ECA Conference Sterile Fill & Finish		✓	
ECA Conference Current Aseptic Technologies		✓	✓
ECA Conference Glass – Glass Breakage – Delamination		✓	✓
ECA Conference Barrier Systems		✓	✓
Trade Show PharmaTechnica		✓	✓

The exact times for the single conferences as well as updates are available in the agenda in the back of the programme and on the Congress website at www.pharma-kongress.com.

The Location

Swissôtel Congress Centrum Düsseldorf / Neuss
 Rheinallee 1
 41460 Neuss
 Tel.: +49 (0) 2131 77 - 00
 Fax: +49 (0) 2131 77 - 1367
 Emailus@swissotel-duesseldorf.de

PLEASE NOTE

There will be no reservations via Concept Heidelberg. Please book your **hotel room directly with the reservation form** which you will receive together with your confirmation/invoice! Charges are payable after receipt of the invoice.

The Fees

One day tickets will enable you to visit the congress either only on day 1 or only on day 2 or on both days. Charges for the one day tickets are € 690,- plus VAT, for the two days ticket € 1.190,- plus VAT (due to the special fees for the congress, ECA membership discounts are not applicable). They include a lunch and beverages during the conferences and in breaks as well as the social event on the evening of the first congress day. Charges are payable after receipt of invoice.

The Social Event



The Social Event at the Pharma Congress is already a tradition, and is networking and relaxation at the same time.

On the evening of the first congress day, on 19 March 2013, all congress delegates and speakers are invited to a „Get together“ in the Congress Center. Take advantage of this opportunity for an information exchange and enjoy the laid-back atmosphere and the entertainment programme.

The Contacts

For questions regarding content:

ECA Conferences Current Aseptic Technologies / Sterile Fill & Finish / Glass – Glass Breakage – Delamination / Barrier Systems:

Dr Andreas Mangel (Operations Director), Tel. +49 6221 84 44 41,
E-Mail: mangel@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Detlef Benesch (Organisation Manager), Tel. +49 6221 84 44 45,
E-Mail: benesch@concept-heidelberg.de.

The Organiser

CONCEPT HEIDELBERG – On behalf of the European Compliance Academy (ECA)
P.O. Box 10 17 64
D-69007 Heidelberg
Phone +49 62 21 84 44-0
Fax +49 62 21 84 44 34
E-Mail: info@concept-heidelberg.de
www.gmp-navigator.com



Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist magazine for the pharmaceutical manufacturing, packaging and supply chain sectors. Every quarterly edition features articles written by key opinion leaders, ranging from pharmaceutical sponsors and key services providers, to industry associations and regulatory authorities. *PMPS* combines technological, operational and corporate perspectives on this growing sector, along with industry interviews, event previews and books reviews.

PLEASE NOTE

Please note that there will **not be any print-outs** at the Congress. Instead you will receive all presentations prior to the Congress as Downloads. All Congress delegates (excluding exhibition visitors) will also receive the presentations on a USB stick at the registration center.

The Trade Show PharmaTechnica

Parallel to the Pharma Congress from 19 and 20 March there will also be taking place the large trade show PharmaTechnica. This show with more than 80 internationally oriented exhibitors will allow you to get to know and to discuss new technologies, products and services as well as to network. For the current exhibitor list please see below or visit the website at www.pharma-kongress.com.


PLEASE NOTE

The PharmaTechnica is also open for visitors who do not want to participate in any of the conferences. However, please note that you will need to register for the free of charge visit of the trade show. The online registration on the website will be active in December 2012. The free visit of the PharmaTechnica does not entitle you to attend any of the conferences.

The PharmaTechnica



The Conferences



The Exhibitors (as of March 2013)

Company	Stand	Company	Stand
ANDERSON-NEGELE	59	iQ-Mobil Solutions	16
ASEPTIC TECHNOLOGIES	60	Kiesel Steriltechnik	31
basan GmbH	9	Laetus	81
Bausch & Ströbel	1	Letzner	23
Belimed	34	Levitronix	52
bioMérieux	15	Lighthouse Instruments	45
Bioquell	56	Mankenberg	25
Bilfinger Industrietechnik	27	Martin Christ	42
Borer	46	Matthews Europe	71
Catalent	28	Müller Cleaning Solutions	12
COMECER	64	multivac	18
Concept GMP Engineering	49	Neumo	67
Datwyler	76	NNE Pharmaplan	30
DEC Deutschland	19	OPTIMA pharma	22
Dockweiler	26	Pall	68
Ellab	24	Particle Measuring Systems	38
ebro Elektronik	43	Pfankuch Maschinen	80
ELPRO Messtechnik	48	PMT Partikel-Messtechnik	53
Esau & Hüber	36	ProSys	78
Extract Technology	44	Rapid Micro Biosystems	79
FEDEGARI	13	Robert Bosch	20
Festo	32	ROMACO	6
Fette Compacting	5	Rota Verpackungstechnik	37
Filtrox	70	rotan	50
Foster Wheeler	77	scanware electronic	66
Franz Ziel	41	SCHOTT	35
Frigo-Trans	58	ServoTech	21
GEA Lyophil	82	SIEMENS	55
GEMÜ	14	Skan	62
Gerresheimer	17	SPC Manufacturing	10
Getinge	61	Stäubli Tec-Systems	39
Glatt	4	Steriline	47
Groninger	40	SWAN	29
Harro Höfliger	2	Telstar Life Sciences	7
Harter	54	Uhlmann	3
HENKEL	69	VITRONIC	65
HEUFT SYSTEMTECHNIK	11	VTU Engineering	8
Höntzsch	74	West	51
International Packaging Systems	33	WILCO	57
Invensys Systems >EUROTHERM<	63		

Speakers

Edgar Bauer	Bausch + Ströbel Maschinenfabrik Ilshofen GmbH + Co. KG, Ilshofen, Germany Has been in charge of the French market in the Sales Department since 2000.
Dr Andrea Behrenswerth	Gerresheimer Bünde GmbH, Bünde, Germany Head of Quality Assurance within Gerresheimer Bünde.
Stefan Bernsau	Harro Höfliger Verpackungsmaschinen GmbH, Allmersbach, Germany Division Leader Pharma Liquids
Dave Boerschel	Catalent Pharma Solutions, Woodstock, USA Program Manager in the R&D department since 2010, leading a group of project managers.
Dr Bettine Boltres	SCHOTT AG, Mitterteich, Germany Product Manager Pharmaceutical Tubing.
Heiko Bütehorn	GEA Diessel GmbH, Hildesheim, Germany Four years management of F&B Division.
Bart E. Burgess	West Pharmaceuticals Services, Lionville, USA Initiated business development for West patch injection systems in 2010.
Christian Doriath	Skan AG, Allschwill, Switzerland Special Operation Engineer.
James Drinkwater	Bioquell UK / PHSS Process and Compliance Director. Chairman of the Pharmaceutical and Healthcare Sciences Society – PHSS.
Leopold Gruber	SBM Schoeller Bleckmann Medizintechnik Ges.m.B., Ternitz, Austria Active from 1974 till the end of 2010 in the area of the design and sales in leading functions.

Dr Roland Guinet	RGmp Compliance, Chevinay, France Consultant Regulatory Compliance Sites and Processes.
Maik Häring	F. Hoffmann-La Roche Ltd, Kaiseraugst, Switzerland
Kathrin Holtei	hameln pharmaceuticals GmbH, Hameln, Germany Assistant to Head of Manufacturing, working on optimizing the efficiency of all areas, especially Barrier systems.
Manfred Holzer	Skan AG, Allschwil, Switzerland Heads the business development of the Skan RABS Systems.
Sascha Karhöfer	West Pharmaceuticals Services, Eschweiler, Germany Manager for Injectable Container Closure Solutions Platform in Europe.
Horst Koller	SCHOTT Schweiz AG Head of technical and quality support syringes.
Dr Timo Krebsbach	Labor L+S AG, Bad Bocklet, Germany Head of the sterility testing department, responsible for sterility tests performed in a cleanroom & isolators.
Dr Thomas Jahnen	HEUFT Systemtechnik GmbH, Burgbrohl, Germany Sales Director Technic.
Uli Kuchenbrod	Vetter Pharma-Fertigung GmbH & Co. KG, Ravensburg, Germany Director Quality Control Incoming Goods.
Dr Jörg Lümekemann	F. Hoffmann-La Roche AG, Basel, Switzerland Heading the dptm. for implementation of new technologies and engineering support for parenteral production.
Gert Moelgaard	NNE Pharmaplan, Søborg, Denmark Vice President for Innovation & Business Development.
Michael de la Montaigne	Bosch Inspection Technology Inc., Allendale/USA Global Sales Director for the inspection machinery (Eisai Machinery).
Dr Daniel Müller	Regierungspräsidium Tübingen, Germany GMP-Inspector with focus on biotechnological active ingredients and sterile drug products.
Dr Wenzel Novak	groninger & co. gmbH, Crailsheim, Germany Responsible for pharmaceutical research and development since 2006.
Matthias Poslowski	OPTIMA pharma gmbh, Schwäbisch Hall, Germany Technical Sales Director.
Dr Tobias Posset	Roche Diagnostics GmbH, Mannheim, Germany Heading the Production Support unit in the Pharma Production in Mannheim.
Dr Ingo Presser	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany Responsible for clinical trial supply and process transfer unit with the Process Science Department.
Dr Heino Prinz	Wilco AG, Wohlen, Switzerland In charge of research and development.
Dr Johannes Rauschnabel	Robert Bosch GmbH, Crailsheim, Germany Director Process Engineering Packaging Technology Pharma.
Dr Andreas Reicke	Vetter Pharma-Fertigung GmbH & Co. KG, Ravensburg, Germany In charge of sterility testing performed in isolators.
Dr Uwe Rothhaar	SCHOTT AG, Mainz, Germany Primarily focused on the chemical resistance and mechanical stability of pharmaceutical primary packing.
Ray Rugebregt	Catalent Pharma Solutions, Woodstock, USA Project Manager in R&D since 2011.
Hartmut Schaz	NNE Pharmaplan GmbH, Bad Homburg, Germany Senior Expert for Small Volume Parenteral Products and is a Director of the Board of NNE Pharmaplan India.
Dr Daniel Scherzinger	Skan AG, Allschwil, Switzerland Head of Scientific Laboratory.
Boris Schmid	Stevanato Group, Piombino Dese, Italy Quality Director focused on Glass Quality- and GMP improvements and worldwide standardization.
Robert Schwarz	Baxter AG, Vienna, Austria Responsible for equipment qualification, sterilisation validation and cleaning validation.
Dominique Sierakowski	Octapharma SA, Lingsheim Head of Corporate Pharmaceutical Production.
Dr Dirk Sievers	Pall Life Sciences GmbH, Dreieich, Germany Technical Marketing Manager.
Paul Stone	Stäubli UK Ltd., Telford, UK General Manager of Stäubli (UK) based in Telford.
Jamie Thompson	GE Analytical Instruments, Dublin, Irland EMEA Applications Specialist.
Stefanie Trudel	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany Head of the new isolator filling line Biopharmaceutical Manufacturing 5.
Benoît Verjans	Aseptic Technologies S.A., Les Isnes, Belgium Currently Commercial Director.
Udo J. Vetter	Vetter Pharma-Fertigung GmbH & Co. KG, Ravensburg, Germany Head of the Control Board of Vetter Companies.
Dr Christian Vogt	Novartis Pharma Stein AG, Basle, Switzerland Head Biological & Microbiological Services.
Dr Andrea Weiland-Waibel	Explicat Pharma GmbH, Hohenbrunn, Germany CMC / Technical project management.
Sokhorn Yim	Genentech, Inc., San Francisco, USA Currently working in Process Development Engineering.
Jörg Zimmermann	Vetter Pharma-Fertigung GmbH & Co. KG, Ravensburg, Germany Director Process Development and Implementation.

Objectives

Why should you attend this conference?

- You will get first hand information on modern filling and finishing technologies, even for sterile fluid and sterile solid products
- Three case studies from pharmaceutical companies will show you different aspects of planning and operating sterile filling lines

Background



Bild: OPTIMA pharma

Sterile fill and finish operations, e.g. the filling of vials, the filling of sterile powders and usage of prefilled syringes, are difficult to handle. In many cases the technologies are rather simple but the requirements for sterility make the process often difficult and complex. Separation of personnel from open processes by Barrier Systems is one of the strategies to avoid microbial contamination.

On the other hand active ingredients become more and more potent / toxic. Therefore filling operations and Barrier Systems must secure personnel from potential contamination as well.

Target Audience


This conference targets staff in the pharmaceutical industry, suppliers and engineering companies responsible for sterile fill and finish activities. Addressed will particularly the areas

- Development
- Production
- Quality Assurance
- Engineering / Technology

Moderator

Hartmut Schaz, NNE Pharmaplan

Programme 19 March

-  9:00 h **Pharma Manufacturing 2020: Development and Investment Strategy – The View of an aseptic filling Company using Platform Technologies**
 ➤ Udo J. Vetter, Vetter Pharma-Fertigung
- What are the trends in aseptic manufacturing
 - Success factors for a growth strategy
 - Extension of capacity and the practical implementation
 - Technical and regulatory challenges for the upcoming years
 - Expectations with regard to planning and engineering companies
- 9:45 h **State of the art production facilities for small volume parenteral products – what makes the difference?**
 ➤ Hartmut Schaz, NNE Pharmaplan
- Building / Layout
 - Process technology
 - Building and process utilities
- 11:00 h **Startup of a multiproduct isolator filling line**
 ➤ Stefanie Trudel, Boehringer Ingelheim Pharma
- Project Scope and timeline for the implementation of 2 high-speed filling lines in isolator technology including layout and product and material flow
 - Line 1 is a vial filling line for liquid and freeze dried products
 - Line 2 is a combiline for vials as well as double chamber cartridges. Both filling lines are linked to the same two freeze dryers
 - Mode of operation as a flexible multiproduct line
 - Lessons learnt from startup and qualification phase
- 11:50 h **Case Study: Highly flexible toxic/aseptic filling of clinical trial material in Prefilled Syringes**
 ➤ Dr Jörg Lümekemann, F. Hoffmann-La Roche
- Process description and zone concept / containment philosophy
 - Stopper handling approach
 - Processability of syringe components
 - Divergence of tub design
 - Binded tray issues
 - Nested syringe optimization

- 14:05 h **Case study: Fill-finish considerations for monoclonal antibodies**
 ➤ Jörg Zimmermann, Vetter Pharma-Fertigung
- Fill-finish process within the scope of pharmaceutical development
 - Typical fill-finish process
 - Formulation
 - Inherent challenges
 - Examples of challenges
 - Source of challenges
 - Case studies
 - Composition of excipients
 - High dose application
 - Susceptibility to interfaces
 - Compatibility to contact material
 - Selection of a medical device
 - Summary
- 14:55 h **Inspection trends & findings in sterile fill & finish**
 ➤ Dr Daniel Müller, Regierungspräsidium Tübingen
- Important updated regulatory guidance documents, e.g.
 - Annex 1 (Rev. 2008), section on capping
 - Trends in manufacture (GMP-inspector's view), e.g.
 - Pre-fillable syringes
 - RABS
 - Single-use disposables
 - Current challenges (GMP-inspector's view)
 - Particles in parenterals / glass breakage / visual inspection
 - Packaging material & containers / leachables & extractables / particles
 - Examples of observations (sterile manufacture)
- 16:15 h **Powder filling in closed containers: from myth to reality**
 ➤ Benoit Verjans / Stefan Bernsau, Aseptic Technologies / Harro Höfliger
- The closed vial technology
 - products dispensed as sterile powders (e.g. Antibiotics)
 - Filling closed vials with powder through the piercing needle
 - Better sterility assurance level
- 17:05 h **Inspection of pre-filled syringes incl. methodology for preparing samples**
 ➤ Michael de la Montaigne, Bosch Inspection Technology
- Technologies used
 - Type(s) of samples
 - Preparing samples
 - Sample verification
 - Bracketing products



Bild: groninger



Bild: Bosch

Objectives

Three good reasons to attend this conference:

- You are informed about the latest technological developments in sterile / aseptic manufacture
- You learn how current GMP and production requirements have to be implemented technologically in sterile manufacture
- You will get the interpretation of new guidelines and regulations from the industry's point of view

Background



Bild: groninger

GMP regulations only define general requirements on equipment – it has to be suitable for the intended work process, easy to clean and without any negative influence on the product quality. The questions of how these general requirements have to be fulfilled concretely in sterile manufacture, which points call for special attention and which new technologies will be used in the future are the focus of this event. Speakers from the pharmaceutical industry, from planning and engineering companies as well as from Inspectorates deal with pivotal developments in the field of sterile manufacture.

Target Audience

The event is directed at specialists from the pharmaceutical industry, at engineers and planners who have to deal with current aseptic technologies in clean areas in their daily practice. It particularly aims at the departments production, quality assurance and engineering / technology.

Moderator

Gert Moelgaard, *NNE Pharmaplan*

Programme 19 March

9:00 h **Pharma Manufacturing 2020: Development and Investment Strategy – The View of an aseptic filling Company using Platform Technologies**

☛ Udo J. Vetter, Vetter Pharma-Fertigung

- What are the trends in aseptic manufacturing
- Success factors for a growth strategy
- Extension of capacity and the practical implementation
- Technical and regulatory challenges for the upcoming years
- Expectations with regard to planning and engineering companies

9:45 h **Aseptic Processing – preparing for the future?**

☛ Gert Moelgaard, NNE Pharmaplan

- Aseptic technologies with new opportunities
- Quality Risk Management and regulatory challenges
- The challenge of convenience in sterile drug delivery systems
- Main trends of the future

11:00 h **Development of a Patch Injection System for Large Volume Biotherapeutics**

☛ Bart Burgess, West Pharmaceuticals Services

- Describes development of a patch injection system for large volume (> 1mL) biotherapeutics
- Development of a container appropriate to these products, current fill/finish technology, and system function
- Development of a drive mechanism that allows for both speed and precision and
- Optimization of human factors starting early in development process to ease user and regulatory acceptance

11:50 h **Working with challenging tech transfers**

☛ Dave Boerschel / Ray Rugebregt, Catalent Pharma Solutions

- Current Aseptic processes and best practice standards
- Examples of customer processes that do not match standards & how to address
- Utilizing automation to retire risk
- Incorporating other continuous improvement activities into a tech transfer
- Results – CTQ (Critical to Quality) scorecards, and KPI's (Key Performance Indicators)

14:05 h **Environmental Monitoring requirements for A/B clean rooms and Isolators aseptic processes**

☛ Roland Guinet, RGmp Compliance

- Particle monitoring
- Microbiological monitoring
- Differences in EU / WHO / FDA-USP requirements
- Specific requirements for A/B clean room – aseptic processes
- Specific requirements for Isolators – aseptic processes
- Result of a 2012 survey on manufacturers' practices

14:55 h **E-Beam for presterilized tubs – Challenges in validation: Dosimetry, Killkinetic, Residuals**

☛ Manfred Holzer, Skan

- Basics of E-Beam Systems for presterilized tubs
- Dosimetry – practical approach & equipment needed
- Killkinetic – 25 KGy dose versus BI-kill
- Residuals O₃, NO_x – measurement & values of the field

- 16:15 h **Different Systems for Fogging and Gassing to decontaminate clean Rooms, Isolators and Lyophilizers**
 ➤ Robert Schwarz, Baxter
- Requirements for a decontamination process
 - Different gassing / fogging systems on the market
 - Qualification of a Dry Fog device
 - Validation of a Dry Fog process
 - Lyophilizer decontamination / chemical sterilization
- 17:05 h **Applying the H₂O₂ process in a vacuum sterilizer for alternative use in the transfer of materials and components**
 ➤ Leopold Gruber, SBM Scholler-Bleckmann Medizintechnik
- H₂O₂ as an alternative method for surface decontamination
 - Vacuum sterilizer equipped with a supplementary H₂O₂ decontamination system
 - Pre-conditions for the using of vacuum sterilizers
 - Application examples
 - Benefits

Programme 20 March

- 9:00 h **Trends in parenteral packaging and the application of QbD-principles to Primary Packaging development and manufacturing**
 ➤ Sascha Karhöfer, West Pharmaceuticals Services
- Current market trends of today's primary packaging requirements
 - How the use of an ultra-clean and dry elastomeric material can improve operational efficiency of drug filling and packaging operations
 - How Quality by Design (QbD) can be implemented into primary packaging component development and manufacturing
 - Applying QbD principles to development and manufacturing of container closure systems
- 9:50 h **Wireless Temperature Measurement in Sterilizers and Parametric Release**
 ➤ Dr Andrea Weiland-Waibel, Explicat Pharma
- Wireless temperature measurement allows precise determination of the product temperature in sterilizer
 - Hot-Cold spot mapping
 - Parametric Release of terminally sterilized parenterals possible
 - The application is of special interest for physically labile products (e.g. Fat Emulsion)
 - Modular system can be installed into existing equipment
- 11:05 h **TD-NMR spectroscopy – a new technology for filling weight determination of parenteral drug solution**
 ➤ Dr Tobias Posset, Roche Diagnostics
- TD-NMR
 - IPC Method
 - Filling weight determination
 - Non-destructive method
 - Parenteral drug solution filled in pre-filled syringes
- 11:55 h **Challenges in Implementing On-line TOC Instruments for Real Time Testing**
 ➤ Jamie Thompson, GE Analytical Instruments
- A shift in the regulatory landscape: EMA updates mandates on RTRT
 - How this impacts you're current state and desired state
 - Real Time Testing has three phases that are all acceptable: Monitoring, Control, Release
 - Implementation steps you need to consider to ensure success
 - Summary highlighting the key "insights / guiding policies from the presentation"
- 14:00 h **Robotics in aseptic processing**
 ➤ Paul Stone / Benoit Verjans, Stäubli / Aseptic Technologies
- Robotics aims to eliminate the operator of the environment
 - Robot system safety by product protection in aseptic processing
 - Two case studies are shown in aseptic processing:
 - Clean and sterile vial manufacturing
 - Aseptic filling
- 15:15 h **Continuous inline blending technology under aseptic conditions with PAT inline analysis**
 ➤ Heiko Bütehorn, GEA Diessel
- General explanation of continuous inline blending technology
 - Possible fields of application in the pharma industry
 - Case study for a pharmaceutical product
 - PAT sensors and process validation
- 16:05 h **Sterile air filtration in critical, high temperature and oxygen-enriched applications**
 ➤ Dr Dirk Sievers, Pall
- Problems of sterile filtration under challenging conditions
 - Comparison of common and new filter materials
 - Integrity testing of vent filter

Objectives

Why you should attend this conference:

- What are the causes of glass defects? You will learn what process steps in the production chain jeopardise the containers
- Delamination is one of the most discussed topics: You will become familiar with how to prevent delamination
- The conference will cover the problems in daily practice and will demonstrate solution approaches making processes safer
- You can discuss questions and problems with inspectors, glass manufacturers, equipment manufacturers and pharmaceutical operators

Background



Delamination and ensuring the integrity of pharmaceutical glass containers for parenterals are currently among the most discussed issues. Various incidents in the recent past led to an increased focus on the topic in authority and customer audits.

That's why in practice "0" defects are either requested or defined as goal. For that purpose the entire process chain from production of the glass tubes to the final packaging has to be carefully checked.

In many process steps there is a lot potential for improvement regarding the reduction and detection of glass defects. This requires an intensive cooperation and exchange of experience of packaging manufacturers and pharmaceutical companies.


Target Audience

This conference targets staff from glass manufacturers, equipment manufacturers and pharmaceutical operators who deal with glass as packaging material every day (development, quality assurance and quality control, production).

Moderator

Dr Wenzel Novak, *groninger*

Programme 19 March

-  9:00 h **Pharma Manufacturing 2020: Development and Investment Strategy – The View of an aseptic filling Company using Platform Technologies**
 ↻ Udo J. Vetter, Vetter Pharma-Fertigung
- What are the trends in aseptic manufacturing
 - Success factors for a growth strategy
 - Extension of capacity and the practical implementation
 - Technical and regulatory challenges for the upcoming years
 - Expectations with regard to planning and engineering companies
- 9:45 h **“Glass – still an option as primary packaging material?”**
 ↻ Horst Koller, SCHOTT Schweiz
- “Actual” issues with glass – facts & figures
 - Regulatory expectations – ambition and reality
 - Glass – advantages & disadvantages
 - Options – Chances, Opportunities, and Limitations
- 11:00 h **Glass breakage – Microcracks – Delamination: Inspector’s point of view**
 ↻ Dr Daniel Müller, Regierungspräsidium Tübingen
- typical genesis of a quality related recall
 - glass breakage & micro cracks - a risk for drug products
 - decision criteria for introducing a recall
 - expectations of a GMP inspector
 - on handling recalls and associated investigations & measures
 - and on detection & mitigation of glass breakage during production process
 - examples of quality issues & recalls based on glass defects
- 11:50 h **Challenges for Glass Containers: Breakage and Delamination**
 ↻ Dr Uwe Rothhaar, SCHOTT
- Introduction to glass as a material for drug containers
 - Characterization of glass breakage – Fractography
 - Container strength – Prediction of overload tests
 - Chemical attack of glass
 - Delamination risk – tailored design of accelerated tests
- 14:05 h **Glass Delamination – Characterization and Prevention from Design to Market**
 ↻ Boris Schmid, Stevanato Group
- Summary of glass delamination studies carried out by Stevanato Group
 - Impact from parameters like glass raw material, surface treatment, forming process considering different buffer solutions
 - Risk assessment and own test method for delamination prediction
 - Overview how to prevent glass delamination from Design to Market

- 14:55 h **Not every Type I glass is the same – differences in Type I glasses and their impact**
 ➔ **Dr Bettine Boltres, SCHOTT**
- Definition and basics of Type I
 - Mechanism of alkali release and surface reactions
 - Type I glasses and differences in release
 - Advantages of a low alkali value
 - Tubing and molded glass production process / Inner and outer surface treatments

- 16:15 h **CMO Interface with Glass Suppliers**
 ➔ **Uli Kuchenbrod, Vetter Pharma-Fertigung**
- Vetter Supplier Management System
 - Specification setting approach
 - CMO challenges on managing multiple product codes
 - Incoming inspection: present and future
 - Examples on lessons learned

- 17:05 h **Panel Discussion on current Glass Issues**

Programme 20 March

- 9:00 h **Final Quality Inspection of primary glass containers for pharmaceutical products**
 ➔ **Dr Heino Prinz, Wilco**
- Combination of various inspection technologies within one inspection device
 - Detection of glass breakage under crimps and stoppers / Functional defects on syringes and vials
 - Needle quality inspection in glass syringes through the needle shield
 - Foreign particles in liquids, suspensions and powders
 - Stopper position and container closure integrities
 - Moisture measurement of product through the glass container
 - Technologies combined: Visual, Y-Ray, Laser Headspace and NIR spectroscopy
- 9:50 h **Minimizing glass container damage with a linear inspection machine**
 ➔ **Dr Thomas Jahnen, HEUFT Systemtechnik**
- Linear inspection machines for full and empty glass vials or syrup bottles avoid stress
 - 100% empty glass inspection to prove the suppliers glass quality
 - Automatic adjustment for different products without the need of format parts
 - Production data acquisition for a complete line analysis – Revealing the weak points of the process
 - Smart conveyor control for a smooth transportation of containers
- 11:05 h **Case Study: Safe glass handling - possibilities for risk mitigation**
 ➔ **Dr Ingo Presser, Boehringer Ingelheim**
- Failure types and causes during the aseptic filling process
 - Risk assessment / Handling of rare events
 - Specifications, tolerances and machines
- 11:55 h **Case study “New parenteral drug product plant at Roche”: Design measures of filling machines to minimize cosmetic defects**
 ➔ **Maik Häring, F. Hoffmann-La Roche**
- Introduction to a new parenteral drug product plant at Roche
 - Requirements/expectations regarding cosmetic defects
 - Design measures to avoid defects during filling:
 - Washing / Sterilization / Depyrogenisation / Transport Glass contact
- 14:00 h **Crack Prevention and process controls in pre-fillable syringe manufacturing**
 ➔ **Dr Andrea Behrenswerth, Gerresheimer Bünde**
- Definition of cracks
 - Development of cracks and prevention, technical solutions
 - Current inspection technology for glass syringes and future development
 - Analysis of syringes with cracks
- 15:15 h **Glass Breakage! Solutions in present-day pharmaceutical machine design**
 ➔ **Edgar Bauer, Bausch + Ströbel**
- What is the current practice
 - Further development based on the previous findings
 - Case study
- 16:05 h **Cosmetic and critical Impacts of fill- and finish lines to glass containers (incl. a case study)**
 ➔ **Dr Wenzel Novak, groninger**
- Handling of primary packaging containers made from glass during the fill process
 - Causes to create damage during filling
 - Options to avoid damage (new design vs. existing equipment)
 - Options to avoid any glass-glass-contact

Objectives

- Case studies from various pharmaceutical companies deal with the implementation and qualification of barrier systems
- You get to know the current state of the art as well as future technological developments in the field of barrier systems
- Which are the weak points of the systems – which operational experience has been gathered? Experts from pharmaceutical companies share their experience with you
- Discuss which points have not yet been managed satisfactorily or need to be improved?

Background



Bild: OPTIMA pharma

Especially in connection with sterile medicinal products produced by aseptic processing, protection against microbial contamination increases in importance. In case of new facilities for sterile manufacturing, the classical cleanroom cannot be considered as the state of the art any longer. Today the supervisory authorities require a more strict separation between staff and product in the form of an access barrier – RABS (Restricted Access Barrier System) or isolator. The level of contamination safety as well as that of personnel protection is clearly higher in both systems. This conference focuses on topical questions on barrier systems in detail from the perspective of pharmaceutical operators, planners and engineers.


Target Audience

The event is directed at decision-makers from pharmaceutical production, development and quality assurance/control, at engineers and planners who need to be well informed about current developments in the field of barrier systems.

Moderator

Jörg Zimmermann, *Vetter Pharma-Fertigung*

Programme 19 March

-  9:00 h **Pharma Manufacturing 2020: Development and Investment Strategy – The View of an aseptic filling Company using Platform Technologies**
 ➔ Udo J. Vetter, Vetter Pharma-Fertigung
- What are the trends in aseptic manufacturing
 - Success factors for a growth strategy
 - Extension of capacity and the practical implementation
 - Technical and regulatory challenges for the upcoming years
 - Expectations with regard to planning and engineering companies
- 9:45 h **Case study: How to run a RABS clean room successfully**
 ➔ Jörg Zimmermann, Vetter Pharma-Fertigung
- Aseptic Process Design
 - Clean Rooms – RABS – Isolator: Advantages and Disadvantages
 - Types of RABS and implications
 - Mock-up studies
 - Daily operations of a RABS
 - Glove integrity testing / Media fills / Monitoring
 - Case studies from real life
- 11:00 h **Pros and Cons of Isolator and Cleanroom based on 10 years of operating experience in sterility testing**
 ➔ Dr Timo Krebsbach, Labor L+S
- Practicability / Reliability / Costs
 - Practical problems and solution strategies
- 11:50 h **Aseptic transfers across a barrier**
 ➔ Benoit Verjans, Aseptic Technologies
- Crossing a wall has been very challenging during many years
 - New transfer solutions, called Rapid Transfer Ports (RTP) have been initially developed for solid transfer whereas the complex “Clean in Place – Steam in Place” (CIP-SIP) remained the leading solution for liquid transfer
 - Some RTP solutions are now applied for liquid transfer
 - A case study is shown with a small and rapid disposable solution, the SART connector
- 14:05 h **Special considerations in Aseptic processing of Biological-Toxic products in Isolators**
 ➔ James Drinkwater, Bioquell / PHSS
- Challenges of processing Aseptic – Biological and Toxic products
 - Control logic to provide aseptic environment, prevent operator exposure and cross contamination
 - Managing compatibility between disinfection agents and Biological products
 - Reducing risk with single use disposable technologies but understanding the process challenges
 - Applying environmental monitoring systems together with contamination risk management
- 14:55 h **A day in the life of an isolator glove: Glove testing and glove lifetime study:**
 ➔ Johannes Rauschnabel, Robert Bosch
- Manual interventions with gloves
 - Glove testing / Simulation of glove use
 - Particle measurement
 - Lifetime study
 - Exchange intervals

- 16:15 h **Glove management**
 ➤ **Kathrin Holtei, hameln pharmaceuticals**
- The journey of gloves through a sterile production area
 - Key parameters for process design
 - Traceability of glove life cycle
 - Lifecycle management at "hameln pharmaceuticals – example for a contract manufacturing company"
 - Most common questions (authorities, customer, supplier)
- 17:05 h **Implementation of a sterility test isolator – a case study**
 ➤ **Dr Andreas Reicke, Vetter Pharma-Fertigung**
- Regulatory background
 - Previous considerations (design, location, utilities)
 - From the planning phase to the start of operation
 - Problems and solutions

Programme 20 March

- 9:00 h **Production and validation concepts of an isolator filling line**
 ➤ **Stefanie Trudel, Boehringer Ingelheim Pharma**
- Microbiological monitoring program
 - Glove procedures including discussion and frequency of physical and visual glove tests
 - Glove tracking and benefit of glove tracking to glove integrity test procedures and microbiological monitoring sampling
 - Media Fill in an isolator
 - Validation of campaign filling
 - Change over times
 - Aseptic handling in an isolator
- 9:50 h **Production thinking by H₂O₂ decontamination in isolators; Relevance of critical parameters on the efficiency of the decontamination cycle**
 ➤ **Christian Doriath, Skan**
- Influence of the parameters like
 - Bio-indicators / Temperature / Relative humidity / low residual concentration
 - Approach for a better process understanding and acceptance
- 11:05 h **Absorption and Adsorption of Vapor Phase Hydrogen Peroxide on Various Filling Components**
 ➤ **Sokhorn Yim, Genentech**
- Hydrogen peroxide ingress through the filling system
 - Hydrogen peroxide uptake based on product height/fill volumes in the vials
 - Determine the saturation point of hydrogen peroxide in different vial sizes
- 11:55 h **Development for Biological Indicators for Hydrogen Peroxide Decontamination**
 ➤ **Dr Daniel Scherzinger, Skan**
- Requirements for Biological Indicators
 - Development of a Biological Indicator for H₂O₂ decontamination processes
 - Goals of project / development / customer review / final product
 - Characteristics and qualification of the Biological Indicator
- 14:00 h **Microbiology in Filling Isolators**
 ➤ **Dr Christian Vogt, Novartis Pharma Stein**
- Bringing an isolator under microbiological control
 - How to achieve a state of "practically free of microorganisms"
 - Control of an isolator with physical and microbiological monitoring
 - Maintenance aspects and integrity checks of isolator systems
 - Validation of an filling isolator with media fills
 - Microbiological problems in isolators
- 15:15 h **Case study: Qualification of an isolator with fast airlock**
 ➤ **Dr Christian Vogt, Novartis Pharma Stein**
- From preparation to the realization: return of experience
 - Major steps in the qualification of an isolator
 - Mapping studies and performance qualification of the decontamination cycle
 - Fast airlock qualification and use in routine
- 16:05 h **Is aseptic filling under isolator realistic in the context of multi-products, multi-formats and high flexibility?**
 ➤ **Matthias Poslovski / Dominique Sierakowski, OPTIMA pharma / Octapharma**
- High value product
 - Wide range of formats / frequency of format changes
 - Small batch sizes
 - Minimize product loss, rejects, down time
 - Isolator was preferred due to higher sterility assurance level
 - Campaigning

Programme 19 March

Time	ECA Conference Current Aseptic Technologies	ECA Conference Sterile Fill & Finish	ECA Conference Glass – Glass Breakage – Delamination	ECA Conference B
9.00 h	 Pharma Manufacturing 2020: Development and Investment Strategy – The View of an aseptic filling Company using Platform Technologies <i>Udo J. Vetter, Vetter Pharma-Fertigung</i>			
9:15 h				
9.30 h				
9:45 h	Aseptic Processing – preparing for the future? <i>Gert Moelgaard, NNE Pharmaplan</i>	State of the art production facilities for small volume parenteral products – what makes the difference? <i>Hartmut Schaz, NNE Pharmaplan</i>	“Glass – still an option as primary packaging material?” <i>Horst Koller, SCHOTT Schweiz</i>	Case study: How to m room successfully <i>Jörg Zimmermann, Vetter</i>
10.00 h				
10:15 h				
10.30 h	Break	Break	Break	Break
10:45 h				
11.00 h	Development of a Patch Injection System for Large Volume Biotherapeutics <i>Bart Burgess, West Pharmaceuticals Services</i>	Startup of a multiproduct isolator filling line <i>Stefanie Trudel, Boehringer Ingelheim Pharma</i>	Glass breakage – Microcracks – Delamination: Inspector’s point of view <i>Dr Daniel Müller, Regierungspräsidium Tübingen</i>	Pros and Cons of Isol based on 10 years of in sterility testing <i>Dr Timo Krebsbach, Labo</i>
11:15 h				
11.30 h				
11:45 h	Break	Break	Break	Break
12.00 h	Working with challenging tech transfers <i>Dave Boerschel / Ray Rugebregt, Catalent Pharma Solution</i>	Case Study: Highly flexible toxic/aseptic filling of clinical trial material in Prefilled Syringes <i>Dr Jörg Lümekemann, F. Hoffmann-La Roche</i>	Challenges for Glass Containers: Breakage and Delamination <i>Dr Uwe Rothhaar, SCHOTT</i>	Aseptic transfers acro <i>Benoit Verjans, Aseptic Tec</i>
12:15 h				
12.30 h				
12:45 h				
13.00 h				
13:15 h	Break	Break	Break	Break
13.30 h				
13:45 h				
14.00 h				
14:15 h	Environmental Monitoring requirements for A/B clean rooms and Isolators aseptic processes <i>Roland Guinet, RGmp Compliance</i>	Case study: Fill-finish considerations for monoclonal antibodies <i>Jörg Zimmermann, Vetter Pharma-Fertigung</i>	Glass Delamination – Characterization and Prevention from Design to Market <i>Boris Schmid, Stevanato Group</i>	Special consideration processing of Biologi Isolators <i>James Drinkwater, Bioque</i>
14:30 h				
14:45 h	Break	Break	Break	Break
15.00 h	E-Beam for presterilized tubs – Challenges in validation: Dosimetry, Killkinetic, Residuals <i>Manfred Holzer, Skan</i>	Inspection trends & findings in sterile fill & finish <i>Dr Daniel Müller, Regierungspräsidium Tübingen</i>	Not every Type I glass is the same – differences in Type I glasses and their impact <i>Dr Bettine Boltres, SCHOTT</i>	A day in the life of an testing and glove lifet <i>Johannes Rauschnabel, R</i>
15:15 h				
15.30 h				
15:45 h	Break		Break	Break
16.00 h				
16:15 h	Different Systems for Fogging and Gassing to decontaminate clean Rooms, Isolators and Lyophilizers <i>Robert Schwarz, Baxter</i>	Powder filling in closed containers: from myth to reality <i>Benoit Verjans / Stefan Bernsau, Aseptic Technologies / Harro Höfliger</i>	CMO Interface with Glass Suppliers <i>Uli Kuchenbrod, Vetter Pharma-Fertigung</i>	Glove management <i>Kathrin Holtei, hameln ph</i>
16:30 h				
16:45 h				
17.00 h	Break	Break	Break	Break
17:15 h	Applying the H ₂ O ₂ process in a vacuum sterilizer for alternative use in the transfer of materials and components <i>Leopold Gruber, SBM Scholler-Bleckmann Medizintechnik</i>	Inspection of pre-filled syringes incl. methodology for preparing samples <i>Michael de la Montaigne, Bosch Inspection Technology</i>	Panel Discussion on current Glass Issues	Implementation of a – a case study <i>Dr Andreas Reicke, Vetter</i>
17:30 h				
17:45 h				
18:00 h	Final Discussion	Final Discussion	Final Discussion	Final Discussion
18.30 h	Social Event for Congress Delegates, Speakers and Exhibitors			



Programme 20 March

Barrier Systems	ECA Conference Current Aseptic Technologies	ECA Conference Glass - Glass Breakage - Delamination	ECA Conference Barrier Systems	Time
	Trends in parenteral packaging and the application of QbD-principles to Primary Packaging development and manufacturing <i>Sascha Karhöfer, West Pharmaceuticals Services</i>	Final Quality Inspection of primary glass containers for pharmaceutical products <i>Dr Heino Prinz, Wilco</i>	Production and validation concepts of an isolator filling line <i>Stefanie Trudel, Boehringer Ingelheim Pharma</i>	9:00 h
				9:15 h
				9:30 h
	Break	Break	Break	9:45 h
Run a RABS clean <i>Pharma-Fertigung</i>	Wireless Temperature Measurement in Sterilizers and Parametric Release <i>Dr Andrea Weiland-Waibel, Explicat Pharma</i>	Minimizing glass container damage with a linear inspection machine <i>Dr Thomas Jahnen, HEUFT Systemtechnik</i>	Production thinking by H ₂ O ₂ decontamination in isolators; Relevance of critical parameters on the efficiency of the decontamination cycle <i>Christian Doriath, Skan</i>	10:00 h
				10:15 h
				10:30 h
	Break	Break	Break	10:45 h
				11:00 h
Isolator and Cleanroom operating experience <i>Dr L+S</i>	TD-NMR spectroscopy - a new technology for filling weight determination of parenteral drug solution <i>Dr Tobias Posset, Roche Diagnostics</i>	Case Study: Safe glass handling - possibilities for risk mitigation <i>Dr Ingo Presser, Boehringer Ingelheim</i>	Absorption and Adsorption of Vapor Phase Hydrogen Peroxide on Various Filling Components <i>Sokhorn Yim, Genentech</i>	11:15 h
				11:30 h
				11:45 h
	Break	Break	Break	12:00 h
Loss a barrier technologies	Challenges in Implementing On-line TOC Instruments for Real Time Testing <i>Jamie Thompson, GE Analytical Instruments</i>	Case study "New parenteral drug product plant at Roche": Design measures of filling machines to minimize cosmetic defects <i>Maik Häring, F. Hoffmann-La Roche</i>	Development for Biological Indicators for Hydrogen Peroxide Decontamination <i>Dr Daniel Scherzinger, Skan</i>	12:15 h
				12:30 h
				12:45 h
	Break	Break	Break	13:00 h
				13:15 h
				13:30 h
				13:45 h
				14:00 h
Issues in Aseptic Critical-Toxic products in <i>ILL / PHSS</i>	Robotics in aseptic processing <i>Paul Stone / Benoit Verjans, Stäubli / Aseptic Technologies</i>	Crack Prevention and process controls in pre-fillable syringe manufacturing <i>Dr Andrea Behrenswerth, Gerresheimer Bünde</i>	Microbiology in Filling Isolators <i>Dr Christian Vogt, Novartis Pharma Stein</i>	14:15 h
				14:30 h
	Break	Break	Break	14:45 h
Isolator glove: Glove time study <i>Robert Bosch</i>	Continuous inline blending technology under aseptic conditions with PAT inline analysis <i>Heiko Bütehorn, GEA Diessel</i>	Glass Breakage! Solutions in present-day pharmaceutical machine design <i>Edgar Bauer, Bausch + Ströbel</i>	Case study: Qualification of an isolator with fast airlock <i>Dr Christian Vogt, Novartis Pharma Stein</i>	15:15 h
				15:30 h
				15:45 h
	Break	Break	Break	16:00 h
Pharmaceuticals	Sterile air filtration in critical, high temperature and oxygen-enriched applications <i>Dr Dirk Sievers, Pall</i>	Cosmetic and critical Impacts of fill- and finish lines to glass containers (incl. a case study) <i>Dr Wenzel Novak, groninger</i>	Is aseptic filling under isolator realistic in the context of multi-products, multi-formats and high flexibility? <i>Matthias Poslovski / Dominique Sierakowski, OPTIMA pharma / Octapharma</i>	16:15 h
				16:30 h
				16:45 h
	Final Discussion	Final Discussion	Final Discussion	17:00 h
				17:15 h
sterility test isolator <i>Pharma-Fertigung</i>				17:30 h
				17:45 h
				18:00 h
				18:30 h



Registration Options

Attending Conferences – One Day Tickets for € 690,-

Attending Conferences – Two Days Tickets for € 1.190,-

With a one day ticket you can attend any conference offered that day. It includes participation in any conference on that day/on both days and the visit of the trade show PharmaTechnica. In addition, it comprises lunch and beverages during the conferences and in breaks (on one or both days) as well as the social event on the evening of the first congress day. Please mark if you would like to attend the Social Event.

To be able to prepare the conference rooms, we would appreciate it if you marked the conference you are interested in. Please also mark the day you plan on attending the Congress. **Please mark only one conference per day.**

I would like to attend on **day 1 (19 March 2013)** and I'm primarily interested in the conference:

- ECA Conference Sterile Fill & Finish
- ECA Conference Current Aseptic Technologies
- ECA Conference Glass – Glass Breakage – Delamination
- ECA Conference Barrier Systems (Isolators/RABS)

I would also like to take part in the Social Event on the evening of 19 March 2013.

I would like to attend on **day 2 (20 March 2013)** and I'm primarily interested in the conference:

- ECA Conference Current Aseptic Technologies
- ECA Conference Glass – Glass Breakage – Delamination
- ECA Conference Barrier Systems (Isolators/RABS)

Visit of the Trade Show PharmaTechnica

(Information on the trade show is also available on the congress website at www.pharma-kongress.com. Please note that the visit of the PharmaTechnica does not include the participation in the conferences. For registering please fill in your personal data below or visit www.pharma-kongress.com and complete the online registration. You will receive a confirmation/invoice for your registration per mail.)

Please mark the day on which you plan on visiting the exhibition:

- Day 1 (19 March 2013) Day 2 (20 March 2013)

If the bill-to-address deviates from the specifications on the right, please fill out here:

CONCEPT HEIDELBERG
 P.O. Box 101764
 Fax +49 (0) 62 21/84 44 34
 D-69007 Heidelberg
 GERMANY

Reservation Form (Please complete in full)

Mr Ms Dr

First name, Surname

Company

Department

Important: Please indicate your company's VAT ID Number

P.O. Number (if applicable)

Street/P.O. Box

City

Zip Code

Country

Phone/Fax

E-Mail (please fill in)

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees: Cancellation
 - until 2 weeks prior to the conference 10 %
 - until 1 weeks prior to the conference 50 %
 - within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as

possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)!